Novo Nordisk pursues sues to stop Hims & Hers from competing with less expensive alternative to Wegovy

Source: CNBC

“Novo Nordisk on Monday said it is suing online telehealth provider Hims & Hers for mass marketing cheaper, unapproved copies of the drugmaker’s new Wegovy obesity pill and injections in the U.S. Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe on the company’s patents and is seeking to recover damages [sic]. … The move escalates the feud between Novo and Hims, which said on Saturday it will stop offering its new copycat obesity pill after facing scrutiny from federal regulators and legal threats from the Danish drugmaker. Hims had planned to offer the oral drug for as little as $49 for the first month, roughly $100 less than Novo’s approved Wegovy pill.” (02/09/26)

https://www.cnbc.com/2026/02/09/novo-nordisk-sues-hims-hers-compounded-obesity-drugs.html